AMAL
Amalgamated Financial Corp.
AMAL's outlook is improving, though it still trails on the overall score.
BAC
Bank of America Corporation
BAC has the edge over AMAL overall, supported by stronger valuation and stronger fundamentals.
AMAL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
AMAL's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like AMAL.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
AMAL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.7x | $31.28 | -38% |
| Fair | 9.8x | $39.80 | -21% |
| Forward | 11x | $50.08 | — |
| Expensive | 12x | $47.33 | -5.5% |
| Current | 12x | $50.08 | — |
Historical ranges are pointers, not guarantees.
AMAL's PE is in its expensive range at 12x. If earnings grow as analysts expect, today's price would be 11x next year's earnings.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over AMAL in the historical PE scenario, which offers more potential upside but is not a forecast.
AMAL Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AMAL, with profitability improving.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
AMAL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.46 | +9.5% |
| Q3 2026 | $4.07 | +23% |
| Q2 2026 | $3.75 | +13% |
| Q1 2026 | $3.44 | +2.4% |
| Q4 2025 | $3.41 | -0.9% |
| Q3 2025 | $3.31 | -2.6% |
| Q2 2025 | $3.33 | +3.1% |
| Q1 2025 | $3.36 | +9.8% |
| Q4 2024 | $3.44 | +20% |
AMAL earned $4.07 per share over the past year, up 23% from the year before.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over AMAL on earnings, with more consistent year-over-year improvement.
AMAL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $101.7M | +19% |
| Q2 2026 | $98.4M | +22% |
| Q1 2026 | $93.4M | +21% |
| Q4 2025 | $85.2M | +9.4% |
| Q3 2025 | $85.6M | +5.6% |
| Q2 2025 | $80.9M | +3.2% |
| Q1 2025 | $77M | -1.6% |
| Q4 2024 | $77.9M | +1.5% |
AMAL's revenue has grown year over year for six quarters in a row: $102M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 48% | +5.5 points |
| Q2 2026 | 47% | +3.6 points |
| Q1 2026 | 36% | -8.7 points |
| Q4 2025 | 39% | -3.4 points |
| Q3 2025 | 43% | -4.3 points |
| Q2 2025 | 44% | -1.8 points |
| Q1 2025 | 45% | -4.1 points |
| Q4 2024 | 42% | -3.5 points |
AMAL has the edge over BAC on profitability, with a higher operating margin.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over AMAL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
AMAL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33M | -14% |
| Q2 2026 | $19.6M | -24% |
| Q1 2026 | $50.7M | +56% |
| Q4 2025 | $38M | +34% |
| Q3 2025 | $38.3M | +8.8% |
| Q2 2025 | $25.6M | -7.7% |
| Q1 2025 | $32.5M | +4.5% |
| Q4 2024 | $28.3M | +88% |
AMAL has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
AMAL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +52K shares |
| 1 year | -0.6% | -170K shares |
| 3 years | -1.1% | -349K shares |
| 5 years | -3.9% | -1.2M shares |
AMAL has 30M diluted shares, down 0.6% from a year ago, with $18M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6.5M |
| Q2 2026 | — |
| Q1 2026 | $2.8M |
| Q4 2025 | $8.7M |
| Q3 2025 | $10.4M |
| Q2 2025 | $9.7M |
| Q1 2025 | $3.5M |
| Q4 2024 | $845,000 |
AMAL spent $18M buying back its own shares over the past year, down 26% from the year before.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over AMAL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
AMAL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 1.7x | Healthy |
AMAL has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
AMAL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.6 | Neutral |
| Stochastic | 66.4 | Neutral |
AMAL's weekly RSI is 63 (neutral) and its Stochastic is 66 (neutral).
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
AMAL PE vs Financial Services Sector
| Metric | AMAL | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 5.5% below |
| PE % | 89 | 63 | 26 pts above |
AMAL is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over AMAL on valuation relative to its sector.
AMAL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $48.7 | 2.8% above |
| 20 week MA | $48.6 | 3.1% above |
| 50 week MA | $42.8 | 17% above |
| 100 week MA | $36.5 | 37% above |
| 200 week MA | $30.1 | 66% above |
AMAL has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
AMAL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.6 | $13.6 | -30% |
| 2021 | $13.6 | $16.7 | +22% |
| 2022 | $16.7 | $23.1 | +39% |
| 2023 | $23.1 | $26.9 | +17% |
| 2024 | $26.9 | $33.7 | +25% |
| 2025 | $33.7 | $32.7 | -3% |
| 2026 YTD | $32.7 | $50.1 | +53% |
AMAL has the edge over BAC on returns for 2026, with the stronger performance.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.